文献速递造血干细胞移植与细胞治疗

胃肠道急性移植物抗宿主病的病理生理学及胰高血糖素样肽2的潜在作用

Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2.
PubMed 文献 · Br J Haematol · 2023-03-25

本文综述胃肠道急性移植物抗宿主病(GI aGVHD)的病理生理新概念,并汇总胰高血糖素样肽2(GLP-2)保护肠道上皮细胞(肠上皮细胞、肠道干细胞和潘氏细胞)的证据,讨论GLP-2治疗作为组织再生策略及新型GLP-2类似物阿普拉鲁肽作为GI aGVHD辅助治疗的理论依据。

要点

  • 全身性类固醇是aGVHD的标准一线治疗,约50%患者出现类固醇难治(SR),预后不良。
  • SR-GVHD现有治疗选择有限,GI aGVHD患者对新非免疫抑制治疗存在显著未满足需求。
  • GLP-2可维护和保护肠上皮细胞、肠道干细胞和潘氏细胞,这些是aGVHD的直接靶细胞。

核心结论

  • GI aGVHD是异基因造血细胞移植后危及生命的并发症和致病致死的主要原因之一。
  • GLP-2治疗作为组织再生策略具有治疗理论依据,新型GLP-2类似物阿普拉鲁肽可能作为GI aGVHD的辅助治疗。

研究设计与样本

  • 综述:总结GI aGVHD病理生理新概念及GLP-2保护肠道上皮细胞的证据,讨论GLP-2治疗理论依据。

主要发现

  • 全身性类固醇是aGVHD的标准一线治疗,约50%患者成为类固醇难治(SR),与不良结局相关。
  • SR-GVHD现有治疗选择有限,GI aGVHD患者对新非免疫抑制治疗存在显著未满足需求。
  • GLP-2在维护和保护肠上皮细胞、肠道干细胞和潘氏细胞中发挥作用,这些细胞是aGVHD的直接靶标。

临床怎么用

  • 作者讨论GLP-2治疗作为组织再生策略的理论依据,以及新型GLP-2类似物阿普拉鲁肽作为GI aGVHD辅助治疗的潜在用途。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic haematopoietic cell transplantation, with gastrointestinal (GI) tract involvement (GI aGVHD) being one of the leading causes of morbidity and mortality. Whilst systemic steroids are the standard first-line treatment for aGVHD, approximately 50% of patients become steroid refractory (SR), which is associated with poor outcomes. Existing options for SR-GVHD are limited, and there is a significant unmet need for new non-immunosuppressive treatment approaches in patients with GI aGVHD. Here, we review newer concepts in the pathogenesis of GI aGVHD and present the evidence for the role of glucagon-like peptide 2 (GLP-2) in maintaining and protecting GI epithelial cells, including the enterocytes, intestinal stem cells and Paneth cells, which are direct targets of aGVHD. Finally, we discuss the therapeutic rationale for GLP-2 treatment as a tissue regeneration approach and the potential use of the novel GLP-2 analogue apraglutide as an adjunctive treatment for GI aGVHD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zeiser R, Chen YB, Youssef NN, et al. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2. Br J Haematol. 2023. PMID: 36965050. doi:10.1111/bjh.18778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。